Publications by authors named "Dyde A Huysmans"
Article Synopsis
- Patients with differentiated thyroid carcinoma and high Tg levels yet negative neck ultrasounds often undergo blind (131)I therapy, but many have negative whole-body scans post-treatment.
- A study tested if (124)I PET/CT imaging could help identify patients who might not need (131)I therapy based on their scan results.
- The preliminary results showed that (124)I PET/CT correctly identified all patients with negative scans, highlighting its potential value in predicting therapy outcomes.
Background: Enhanced reduction of multinodular goiter (MNG) can be achieved by stimulation with recombinant human thyrotropin (rhTSH) before radioiodine ((131)I) therapy. The objective was to compare the long-term efficacy and safety of two low doses of modified release rhTSH (MRrhTSH) in combination with (131)I therapy.
Methods: In this phase II, single-blinded, placebo-controlled study, 95 patients (57.
Background: To date, no valid instrument is available that focuses on specific health-related quality of life (HRQoL) issues that affect thyroid cancer survivors. The objective of this study was to develop and pretest a thyroid cancer specific HRQoL questionnaire that can be used in addition to the more general European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).
Material And Methods: Potentially relevant issues were identified by a systematic literature review, a focus group meeting, and an issue list completed by six health care professionals (HCP) and 18 thyroid cancer survivors.
Article Synopsis
- The study assessed how the implementation of FDG-PET scanning affected adherence to mediastinal staging protocols and the use of mediastinoscopy in patients with non-small-cell lung cancer.
- Data from 143 patients across three time periods were analyzed, showing an improvement in guideline adherence for performing mediastinoscopy post-PET implementation.
- Although the optimal yield of mediastinoscopy slightly decreased, the rate of positive findings for metastases increased, suggesting that while fewer procedures were optimal, more were still valuable for diagnosis.
Unlabelled: A single, low dose of recombinant human thyroid-stimulating hormone (rhTSH) doubles 24-h RAIU and causes a more homogeneous distribution of radioiodine on thyroid scintigrams of patients with nodular goiter. Pretreatment with rhTSH allows the therapeutic dose of (131)I to be reduced by 50%-60% without compromising the result of thyroid volume reduction. The present study focused on the dosimetric aspects of therapy with a reduced dose of (131)I after pretreatment with rhTSH in patients with nodular goiter.
View Article and Find Full Text PDFIn patients with nodular goiter, radioiodine ((131)I) therapy results in a mean reduction in thyroid volume (TV) of approximately 40% after 1 yr. We have demonstrated that pretreatment with a single, low dose of recombinant human TSH (rhTSH) doubles 24-h radioactive iodine uptake (RAIU) in these patients. We have now studied the safety and efficacy of therapy with a reduced dose of (131)I after pretreatment with rhTSH.
View Article and Find Full Text PDF